Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aims. To investigate the costs and cost-effectiveness of a short message service (SMS) intervention to prevent the onset of type 2 diabetes mellitus (T2DM) in subjects with impaired glucose tolerance (IGT).Methods. A Markov model was developed to simulate the cost and effectiveness outcomes of the SMS intervention and usual clinical practice from the health provider’s perspective. The direct programme costs and the two-year SMS intervention costs were evaluated in subjects with IGT. All costs were expressed in 2011 US dollars. The incremental cost-effectiveness ratio was calculated as cost per T2DM onset prevented, cost per life year gained, and cost per quality adjusted life year (QALY) gained.Results. Within the two-year trial period, the net intervention cost of the SMS group was $42.03 per subject. The SMS intervention managed to reduce 5.05% onset of diabetes, resulting in saving $118.39 per subject over two years. In the lifetime model, the SMS intervention dominated the control by gaining an additional 0.071 QALY and saving $1020.35 per person. The SMS intervention remained dominant in all sensitivity analyses.Conclusions. The SMS intervention for IGT subjects had the superiority of lower monetary cost and a considerable improvement in preventing or delaying the T2DM onset. This trial is registered with ClinicalTrials.gov NCT01556880.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 7×
“The annual transition probability from IGT to T2DM in the usual practice group in the first three years was adopted from the results of the placebo arm in Diabetes Prevention Program (DPP) [27], whereas the Diabetes Prevention Program Outcome Study (DPPOS) [28] provided this transition probability for the fourth year…”
BackgroundMethodInfluentialGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147 · cited 1×
“An annual discount rate of 3% was undertaken in both the cost and health outcomes as per the Panel on Cost-Effectiveness in Health and Medicine recommended [25].”
MethodFree, C., Knight, R., Robertson, S., Whittaker, R., Edwards, P., Zhou, W., Rodgers, A., Cairns, J., Kenward, M. G., & Roberts, I. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60701-0 · Cited by 728
Herman, W. H., Hoerger, T. J., Brandle, M., Hicks, K., Sorensen, S., Zhang, P., Hamman, R. F., Ackermann, R. T., Engelgau, M. M., Ratner, R. E., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00007 · Cited by 703
Risk models and scores for type 2 diabetes: systematic review
Noble, D., Mathur, R., Dent, T., Meads, C., & Greenhalgh, T. (2011) · BMJ · doi:10.1136/bmj.d7163 · Cited by 551 · cited 1×
“Studies indicated that prediabetes is a major factor leading to diabetes [5], and people with prediabetes have increased risk of cardiovascular disease (CVD) and mortality [6–8].”
BackgroundThe 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention
The Diabetes Prevention Program Research Group (2012) · Diabetes Care · doi:10.2337/dc11-1468 · Cited by 436
Diabetes Self-Management Care via Cell Phone: A Systematic Review
Krishna, S., & Boren, S. A. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200324 · Cited by 225 · cited 1×
“Over the past decade, self-management education or support by mobile-based applications has been launched to target the blood glucose and HbA1C levels control in patients with type 2 diabetes mellitus (T2DM) [9].”
BackgroundPalmer, A. J., Roze, S., Valentine, W. J., Spinas, G. A., Shaw, J. E., & Zimmet, P. Z. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90029-x · Cited by 128
Cited by
Iribarren, S. J., Cato, K., Falzon, L., & Stone, P. W. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170581 · Cited by 519
Zhou, X., Siegel, K. R., Ng, B. P., Jawanda, S., Proia, K. K., Zhang, X., Albright, A. L., & Zhang, P. (2020) · Diabetes Care · doi:10.2337/dci20-0018 · Cited by 173
Decision models of prediabetes populations: A systematic review
Leal, J., Morrow, L. M., Khurshid, W., Pagano, E., & Feenstra, T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13684 · Cited by 30
Metadata
- Authors
- Wong, C. K. H., Jiao, F.-F., Siu, S.-C., Fung, C. S. C., Fong, D. Y. T., Wong, K.-W., Yu, E. Y. T., Lo, Y. Y. C., & Lam, C. L. K.
- Venue
- Journal of Diabetes Research
- Publisher
- Hindawi Limited
- Published
- 2016
- Volume
- 2016
- Pages
- 1-8
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- OpenAlex
- W2259589578
- Cited by
- 39
- References
- 12
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.